GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aarti Drugs Ltd (BOM:524348) » Definitions » Cyclically Adjusted Revenue per Share

Aarti Drugs (BOM:524348) Cyclically Adjusted Revenue per Share : ₹247.87 (As of Mar. 2025)


View and export this data going back to 1993. Start your Free Trial

What is Aarti Drugs Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Aarti Drugs's adjusted revenue per share for the three months ended in Mar. 2025 was ₹74.149. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹247.87 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Aarti Drugs's average Cyclically Adjusted Revenue Growth Rate was 6.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Aarti Drugs was 11.20% per year. The lowest was 9.60% per year. And the median was 10.40% per year.

As of today (2025-05-16), Aarti Drugs's current stock price is ₹455.00. Aarti Drugs's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹247.87. Aarti Drugs's Cyclically Adjusted PS Ratio of today is 1.84.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Aarti Drugs was 5.97. The lowest was 1.33. And the median was 2.26.


Aarti Drugs Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Aarti Drugs's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aarti Drugs Cyclically Adjusted Revenue per Share Chart

Aarti Drugs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 170.07 188.52 213.94 233.68 247.87

Aarti Drugs Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 233.68 239.48 244.44 246.84 247.87

Competitive Comparison of Aarti Drugs's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Drugs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarti Drugs's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Drugs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Aarti Drugs's Cyclically Adjusted PS Ratio falls into.


;
;

Aarti Drugs Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aarti Drugs's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=74.149/157.3313*157.3313
=74.149

Current CPI (Mar. 2025) = 157.3313.

Aarti Drugs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 29.240 99.841 46.077
201509 28.158 101.753 43.538
201512 27.348 102.901 41.814
201603 32.427 102.518 49.765
201606 30.081 105.961 44.664
201609 32.518 105.961 48.283
201612 30.670 105.196 45.870
201703 31.322 105.196 46.845
201706 27.063 107.109 39.753
201709 33.449 109.021 48.271
201712 35.151 109.404 50.550
201803 35.057 109.786 50.239
201806 39.319 111.317 55.572
201809 36.810 115.142 50.298
201812 40.311 115.142 55.081
201903 48.688 118.202 64.806
201906 43.162 120.880 56.178
201909 51.245 123.175 65.455
201912 50.806 126.235 63.321
202003 48.244 124.705 60.866
202006 58.441 127.000 72.398
202009 62.029 130.118 75.002
202012 56.894 130.889 68.388
202103 53.836 131.771 64.279
202106 62.630 134.084 73.489
202109 62.594 135.847 72.493
202112 68.553 138.161 78.065
202203 74.975 138.822 84.972
202206 67.166 142.347 74.236
202209 74.185 144.661 80.683
202212 71.702 145.763 77.393
202303 79.042 146.865 84.675
202306 71.394 150.280 74.744
202309 69.778 151.492 72.468
202312 65.906 152.924 67.805
202403 67.434 153.035 69.327
202406 60.402 155.789 61.000
202409 65.556 157.882 65.327
202412 60.984 158.323 60.602
202503 74.149 157.331 74.149

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Aarti Drugs  (BOM:524348) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Aarti Drugs's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=455.00/247.87
=1.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Aarti Drugs was 5.97. The lowest was 1.33. And the median was 2.26.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Aarti Drugs Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Aarti Drugs's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aarti Drugs Business Description

Industry
Traded in Other Exchanges
Address
Road No. 29, Plot Number 109-D, Mahendra Industrial Estate, Ground Floor, Sion (East), Mumbai, MH, IND, 400022
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.

Aarti Drugs Headlines

No Headlines